Amanta Healthcare IPO Subscription Reaches 82.60 Times on Day 3

The Amanta Healthcare IPO has received a strong response from investors, with a subscription of 82.60x by the end of Day 3. The company is offering shares at a price of Rs. 126 per share, with a minimum lot size of 119 shares. The issue size stands at 1,00,00,000 shares (aggregating up to Rs 126.00 crore), comprising only fresh issues. Stay tuned for the latest updates on the Amanta Healthcare IPO subscription status as the offering progresses.

Amanta Healthcare IPO Subscription Status - Day 3

The Amanta Healthcare IPO was subscribed 82.60 times on Day 3, with Retail Investors at 54.96 times, Non-Institutional Investors (NIIs) with a demand at 209.40 times, and Qualified Institutional Buyers (QIBs) at 35.86 times.

Last updated: 05:04 PM, Wednesday, 03 Sept 2025

Amanta Healthcare IPO Subscription Status - Day 2

The Amanta Healthcare IPO was subscribed 19.63 times on Day 2, with Retail Investors at 23.35 times, Non-Institutional Investors (NIIs) with a demand at 36.41 times, and Qualified Institutional Buyers (QIBs) at 0.53 times.

Last updated: 05:04 PM, Tuesday, 02 Sept 2025

Amanta Healthcare IPO Subscription Status - Day 1

The Amanta Healthcare IPO was subscribed 4.62 times overall by the end of Day 1, with Retail Investors at 6.72 times, Non-Institutional Investors (NIIs) with a demand at 5.82 times, and Qualified Institutional Buyers (QIBs) at 0.04 times.

Last updated: 05:04 PM, Monday, 01 Sep 2025

Company Overview of the Amanta Healthcare IPO

Amanta Healthcare Limited, incorporated in 1994 and renamed in 2014, is a leading Ahmedabad-based pharmaceutical company specializing in sterile liquid formulations. Its product portfolio spans IV fluids, respiratory solutions, ophthalmics, injectables, anti-infectives, diluents, and IV sets. The company operates a state-of-the-art manufacturing facility at Hariyala, Kheda (Gujarat), equipped with advanced Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) SteriPort technology across multiple Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) lines. This is supported by in-house formulation development and quality control labs. With WHO-GMP and international certifications, Amanta ensures compliance with stringent global standards, serving both domestic and international markets.

The company has a significant production scale with an annual installed capacity of over 56.6 million LVP bottles, 209.1 million SVP bottles, and 66.2 million SteriPort units. Its products reach more than 47 countries, strengthening its global footprint. Backed by an experienced management team and around 123 skilled professionals.

Strengths and Risks of Amanta Healthcare IPO

Let’s dive into the strengths and risks to assess if the Amanta Healthcare IPO is good or bad for investors

Strengths

• Amanta Healthcare is a specialized pharmaceutical company with expertise in sterile liquid formulations covering a wide product range, including IV fluids, ophthalmics, injectables, anti-infectives, diluents, respiratory and irrigation solutions.

• The company operates a state-of-the-art manufacturing facility equipped with advanced Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) SteriPort technologies that enhance precision and safety in production.

• It maintains significant production capacity with multiple manufacturing lines for large volume parenterals (LVPs) and small volume parenterals (SVPs), supported by dedicated in-house formulation and quality control laboratories.

• Amanta’s facilities have garnered important international certifications such as WHO, ISO, cGMP, and DNV certifications, enabling access to regulated global markets.

• The company boasts strong operational efficiency with high capacity utilization rates and a diversified product portfolio of over 45 products marketed under its own brands.

Risks

• The company’s manufacturing operations are concentrated in a single facility in Gujarat, exposing it to operational risks from production disruptions, regulatory actions, or natural calamities at that site.

• Amanta is subject to raw material cost fluctuations, particularly petrochemical-based inputs like LDPE and polypropylene, which can impact its margins amid volatile commodity prices.

• High financial leverage and associated interest costs pose risks to profitability and cash flow stability, especially if future earnings growth does not meet expectations.

• The pharmaceutical industry is highly competitive, and Amanta faces pricing pressures from both established domestic and international players in the sterile formulation segment.

• Regulatory risks are notable, including past regulatory scrutiny and litigation that could cause financial penalties or operational interruptions.

Amanta Healthcare IPO Details

• IPO Date: September 1 to September 3, 2025

• Issue Price: Rs 120 to Rs 126 per share

• Lot Size: 119 shares

• Total Issue Size: 1,00,00,000 shares (aggregating up to Rs 126.00 crore)

• Tentative Allotment Date: Thursday, September 4, 2025

• Tentative Listing Date: Tuesday, September 9, 2025

How to Apply for Amanta Healthcare IPO

• Visit the Rupeezy app or Rupezy DOCK.

• Navigate to the IPO section on the Home Page

• Here, you can view all the IPOs with details such as market lot, minimum bid quantity, price range, and analysis.

• You can read the Red Herring Prospectus for the issue details.

• Click on Apply.

• Enter your UPI ID for payment & place the bid.

• While placing the bid, enter the cutoff price or desired price in the range specified. Select quantity as per lot size. 

• Submit to complete the order.